The stock may react negatively to the EPS miss and dilution, but the financing secures funding through the pivotal 2027 data readout, reducing near-term liquidity risk — monitor enrollment progress and upcoming trial updates.
Price Chart
Executive Summary
Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.
Key Financial Metrics
Key Facts
- Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
- No revenue reported for the period
- Closed $10M underwritten public offering, extending cash runway to Q2 2027
- Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027
- FDA to accept integrated safety data from both AD and PD trials for NDA submission
- Parkinson's open-label study 28% enrolled since February 2026
Financial Impact
Dilutive offering of $10M at a loss-making stage; EPS miss of 8.3% but cash secured for key milestones
Risk Factors
- Dilution from $10M public offering
- No revenue and continued losses; dependence on trial outcomes
- Clinical trial delays or negative data could derail NDA timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3271713 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access